Evidence‑Based CPAP Fitting and Management for Obstructive Sleep Apnea

Diagnosis and Severity Assessment

The American Academy of Sleep Medicine (AASM) recommends that CPAP therapy be initiated only after OSA is confirmed by polysomnography (PSG) or home sleep apnea testing (HSAT). 1
A minimum of 4 hours of technically adequate oximetry and airflow data is required for a valid diagnostic study. 3
An apnea‑hypopnea index (AHI) ≥ 5 events/h defines OSA; treatment is indicated for AHI ≥ 15 (events/h) or for AHI 5‑15 when significant symptoms or cardiovascular comorbidities are present (American Geriatrics Society, AGS). 5
Patients with moderate‑to‑severe pulmonary disease, neuromuscular disease, congestive heart failure, chronic opioid use, prior stroke, or suspected hypoventilation syndromes should undergo attended in‑laboratory PSG rather than HSAT (AGS). 5
Home sleep testing is contraindicated in the above high‑risk groups because it may miss complex sleep‑disordered breathing patterns (AASM). 1

Severe claustrophobia may preclude CPAP use; appropriate mask fitting, gradual desensitization, and education can mitigate this barrier (AGS). 5
Absolute contraindications include acute facial trauma, recent facial/upper‑airway surgery, severe facial deformities, pneumothorax, pneumomediastinum, and cerebrospinal‑fluid leak (AGS). 5
Severe bullous lung disease warrants careful evaluation due to theoretical risk of pneumothorax, although high‑quality evidence is limited (AGS). 5

Three primary mask types are available: nasal mask, nasal pillows, and oronasal (full‑face) mask (AGS). 5
Nasal masks or nasal pillows are the preferred initial choice for patients who can keep the mouth closed during sleep, as they reduce dead space and claustrophobia (AGS). 5
Oronasal masks are indicated for obligate mouth breathers, patients with significant nasal obstruction, or when therapeutic pressures exceed 15 cmH₂O (AGS). 5

The AASM defines attended PSG‑based CPAP titration (either split‑night or dedicated titration study) as the gold‑standard method for determining optimal pressure (AASM & AGS). [5][2]
Split‑night titration is appropriate when OSA is confirmed after ≥ 2 hours of diagnostic sleep and the AHI is ≥ 15 (events/h) (AGS). 5
Pressure is increased in 1–2 cmH₂O increments until apneas, hypopneas, respiratory‑effort‑related arousals, and snoring are eliminated across all sleep stages and body positions (AGS). 5
The optimal pressure is the lowest level that controls respiratory events without inducing central apneas or causing patient intolerance (AGS). 5
Auto‑adjusting CPAP (APAP) devices automatically modify pressure breath‑by‑breath based on airflow limitation, snoring, or apneas (AGS). 5
APAP may be used as initial therapy for uncomplicated moderate‑to‑severe OSA in patients without significant cardiopulmonary comorbidities (AASM). 2
APAP is not appropriate for patients with congestive heart failure, COPD, central sleep apnea, or hypoventilation syndromes (AGS). 5
Typical therapeutic pressures range from 5 to 20 cmH₂O, with most patients requiring 8 to 12 cmH₂O (AGS). 5

Hands‑on demonstration of mask application/removal, device power‑on/off, humidifier filling, and basic troubleshooting is essential (AGS & AASM). [5][1]
Effective CPAP use is defined as ≥ 4 hours per night on ≥ 70 % of nights; a dose‑response benefit is observed even at 2 hours/night (Praxis 2025). 6
Weight loss of ≈ 10 % of body weight significantly improves AHI and may lower required CPAP pressure (AGS). 5
Patients should avoid alcohol, sedative‑hypnotics, and opioids because these agents depress upper‑airway tone and worsen OSA (AGS). 5
Gradual desensitization—wearing the mask while awake for progressively longer periods—helps patients with claustrophobia; nasal pillows are a useful initial option (AGS). 5

Early objective follow‑up within 3–7 days of CPAP initiation (week 1) is recommended to assess tolerance, address side effects, and review device download data (Praxis 2025). 6
Abandonment during the first week strongly predicts long‑term non‑adherence; prompt intervention is critical (Praxis 2025). 6
Residual AHI > 5–10 events/h on CPAP indicates inadequate pressure or persistent central events and warrants reassessment (Praxis 2025). 6

Older adults tolerate CPAP as well as younger patients when properly fitted and educated (AGS). 5

CPAP reduces cardiac afterload and improves left‑ventricular function in heart‑failure patients with OSA (AGS). 5
Adaptive servo‑ventilation (ASV) is contraindicated in heart failure with reduced ejection fraction because of increased mortality risk (Praxis 2026). 7

Patients with COPD‑OSA overlap require careful titration due to hypercapnia risk and may benefit from bilevel PAP rather than CPAP (AGS). 5

Patients scheduled for bariatric or upper‑airway surgery should undergo pre‑operative PSG to diagnose and treat OSA perioperatively (AASM). 1
Peri‑operative CPAP use reduces postoperative complications in OSA patients (AGS). 5

Do not rely solely on clinical prediction tools or questionnaires for OSA diagnosis; objective testing is mandatory (Praxis 2026). 4
Do not assume all apneas are obstructive; central sleep apnea requires different management and may be worsened by CPAP (Praxis 2026). 7
Do not ignore early adherence problems; intervene within the first week to improve long‑term success (Praxis 2025). 6
Do not use APAP in patients with heart failure, COPD, or central sleep apnea; attended titration is required (AGS). 5
Recognize that residual AHI definitions vary among CPAP manufacturers; interpret device data in clinical context (Praxis 2025). 6